FDA Approves Zanidatamab for Gastric Cancer
The August 25, 2026, decision introduces new treatment regimens for HER2-positive gastric and esophageal cancers.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Do you feel new, specialized cancer treatments are improving patient care in your area?
On August 25, 2026, the FDA approved zanidatamab-based regimens for the first-line treatment of HER2-positive gastric, GEJ, and esophageal adenocarcinoma. The approval is linked to the use of companion diagnostic tests to ensure patients meet the specific IHC 3+ tumor criteria.
Why it matters
The clinical shift away from traditional trastuzumab-led approaches toward bispecific antibodies and antibody-drug conjugates reflects evolving standards for treating advanced gastric cancers. This regulatory milestone provides new therapeutic options aimed at extending survival for patients with HER2-positive disease.
Phase III HERIZON-GEA-01 trial results reported a 12.4-month median progression-free survival for zanidatamab-based regimens. The combination arm involving zanidatamab, tislelizumab, and chemotherapy achieved a median overall survival of 26.4 months.
The players
FDA
The United States Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products.
The details
Treatment protocols in the HERIZON-GEA-01 study required patients to undergo anti-diarrheal prophylaxis during their initial cycle. The approval process mandates that clinicians verify patient eligibility through government-approved companion diagnostic testing.
Timeline
2022: Japan recorded more than 125,000 gastric cancer cases.
March 2026: Japan expanded trastuzumab deruxtecan usage.
May 27, 2026: The HERIZON-GEA-01 trial results were published.
June 19, 2026: Japan approved durvalumab for gastric cancer treatment.
August 25, 2026: The FDA approved zanidatamab-based first-line regimens.
The Big Picture
This approval marks a significant shift in oncological treatment paradigms by building upon the data outcomes established by the HERIZON-GEA-01 trial. It represents a broader departure from legacy trastuzumab-led therapies toward more targeted bispecific antibody approaches.
Patients diagnosed with HER2-positive gastric or esophageal cancers now have new therapeutic options that utilize zanidatamab in combination with chemotherapy and tislelizumab. Clinical access is contingent on testing for IHC 3+ tumor status to determine eligibility for these specific regimens.
The takeaway
The move toward bispecific antibody treatments underscores the medical community's progress in developing highly specific therapies for advanced gastric cancer. Patients should consult their oncologists to determine if diagnostic testing qualifies them for these newly approved treatment pathways.
Further reading
Learn more about the latest advancements in oncology at the Cancer section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you feel new, specialized cancer treatments are improving patient care in your area?
